Cardiomyopathy and Precision Medicine 2nd Edition

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".

Deadline for manuscript submissions: 25 December 2024 | Viewed by 2196

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cardiology, National Defense Medical College, Tokorozawa, Saitama, Japan
Interests: heart failure; cardiomyopathy; autoimmunity; microbitoa; biomarkers; genetic testing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The diagnosis of the most common forms of cardiomyopathies, dilated and hypertrophic cardiomyopathies, have long been based on morphology and function by non-invasive diagnostic modalities (e.g., echocardiography). In addition, despite extensive studies on biophysical, cellular, and animal models, the current approaches to the management of patients with cardiomyopathies remain largely unchanged.

Recent advances in genetics, proteomics, metabolomics, and microbiomics have broadened our understanding of the molecular and cellular pathophysiology of cardiovascular diseases including cardiomyopathies, which can potentially lead to more precise risk prediction and the discovery of optimal treatment strategies for individual patients. Also, novel approaches, such as artificial intelligence and machine learning to medical big data from various sources including clinical registries, electronic health records, biomarkers, medical images, and all spectrum of ‘omics’ data (e.g., genomic, proteomic, and metabolomic data), have huge potential for empowering personalized medicine for cardiomyopathy patients.

This Special Issue of the Journal of Personalized Medicine aims to highlight the current knowledge and future perspectives in the potential analytic approaches leading to personalized medicine for cardiomyopathies.

Dr. Yuji Nagatomo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiomyopathy
  • personalized medicine
  • genetics
  • proteomics
  • metabolomics
  • microbiomics
  • genome-wide association study
  • single-nucleotide polymorphism
  • artificial intelligence
  • machine learning

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 725 KiB  
Article
The Association of M235T Genetic Polymorphism in Angiotensinogen Gene and Other Non-Genetic Factors with Essential Hypertension among Jordanian Patients
by Hussein Alhawari, Yazun Jarrar, Malek Zihlif, Ayman Wahbeh, Sameeha Alshelleh, Ruba Alhabahbeh and Dalia Abdelrazaq
J. Pers. Med. 2024, 14(3), 273; https://doi.org/10.3390/jpm14030273 - 29 Feb 2024
Viewed by 1094
Abstract
Background: Hypertension, characterized by elevated pressure, poses a significant health risk. Recent studies in Jordan highlight high hypertension rates, emphasizing the need for genetic investigations to comprehend essential hypertension determinants. The AGT gene, part of the Renin Angiotensin System, is linked to blood [...] Read more.
Background: Hypertension, characterized by elevated pressure, poses a significant health risk. Recent studies in Jordan highlight high hypertension rates, emphasizing the need for genetic investigations to comprehend essential hypertension determinants. The AGT gene, part of the Renin Angiotensin System, is linked to blood pressure regulation. Limited information exists on the frequency of this polymorphism among Jordanian hypertensive patients. Aims: This study explores the association between the AGT M235T polymorphism and essential hypertension in Jordan. Methods: A cross-sectional study with 435 participants (199 hypertensive, 236 non-hypertensive) was conducted at the University of Jordan Hospital. Blood pressure was measured, and genetic analysis of the AGT M235T polymorphism was completed using the PCR-RFLP technique. Chi-square and t-tests were used for comparisons using SPSS software. Results: Hypertensive patients exhibited significantly higher weight, BMI, and blood pressure. Genotyping results showed no significant difference (p > 0.05, Chi-square) in AGT M235T polymorphism distribution between control and patient groups. In addition, allele frequencies showed comparable patterns (p > 0.05, Chi-square). All genotype frequencies showed no deviation from the Hardy–Weinberg equation (p > 0.05, Chi-square). Conclusions: The AGT M235T genetic polymorphism is not more prevalent among hypertensive patients in Jordan, although the average weight and BMI among hypertensive patients is higher than the non-hypertensive participants. Obesity can be addressed as a potential risk factor for essential hypertension in Jordan. In addition, it is recommended to find out the influence of the AGT M235T genetic polymorphism on the response of antihypertensive drugs among hypertensive patients in Jordan. Full article
(This article belongs to the Special Issue Cardiomyopathy and Precision Medicine 2nd Edition)
Show Figures

Figure 1

Review

Jump to: Research

14 pages, 597 KiB  
Review
Fluid Restriction for Patients with Heart Failure: Current Evidence and Future Perspectives
by Naoko P. Kato, Yuji Nagatomo, Fujimi Kawai, Takeshi Kitai and Atsushi Mizuno
J. Pers. Med. 2024, 14(7), 741; https://doi.org/10.3390/jpm14070741 - 11 Jul 2024
Viewed by 781
Abstract
Fluid restriction has long been believed to benefit patients with heart failure by counteracting the activated renin–angiotensin aldosterone system and sympathetic nervous activity. However, its effectiveness remains controversial. In this paper, we summarized the current recommendations and reviewed the scientific evidence on fluid [...] Read more.
Fluid restriction has long been believed to benefit patients with heart failure by counteracting the activated renin–angiotensin aldosterone system and sympathetic nervous activity. However, its effectiveness remains controversial. In this paper, we summarized the current recommendations and reviewed the scientific evidence on fluid restriction in the setting of both acute decompensated heart failure and compensated heart failure. While a recent meta-analysis demonstrated the beneficial effects of fluid restriction on both all-cause mortality and hospitalization compared to usual care, several weaknesses were identified in the assessment of the methodological quality of the meta-analysis using AMSTAR 2. Further randomized controlled trials with larger sample sizes are needed to elucidate the benefits of fluid restriction for both clinical outcomes and patient-reported outcomes in patients with heart failure. Full article
(This article belongs to the Special Issue Cardiomyopathy and Precision Medicine 2nd Edition)
Show Figures

Figure 1

Back to TopTop